Pharma IQ | 09/22/2010
When carried out well, adaptive trials not only provide evidence of safety and efficacy more quickly, but also allow you to assess that evidence and get answers earlier. In this interview John Johnson, Senior Biostatistician at Cato Research, speaks to Andrea Charles from Pharma IQ, about the three key strategies for effective use of adaptive trials in drug development and the implementation hurdles small pharma and biotech companies face.
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma & Health 2024
September 10 - 12, 2024
Düsseldorf, Germany
Register Now |
View Agenda |
Learn More
Temperature Control and Logistics North America Summit
September 10 - 12, 2024
Falls Church, VA
Register Now |
View Agenda |
Learn More